Last reviewed · How we verify
FOLFIRI.3
FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells.
FOLFIRI is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, irinotecan, and folinic acid to target rapidly dividing cancer cells. Used for Metastatic colorectal cancer.
At a glance
| Generic name | FOLFIRI.3 |
|---|---|
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Drug class | Chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The combination of these drugs works synergistically to inhibit thymidylate synthase, topoisomerase I, and other enzymes essential for DNA replication and cell division. This leads to DNA damage and ultimately cell death in rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
Key clinical trials
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer (EARLY_PHASE1)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFIRI.3 CI brief — competitive landscape report
- FOLFIRI.3 updates RSS · CI watch RSS
- Federation Francophone de Cancerologie Digestive portfolio CI